Serina <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures $20 Million Convertible Note with Board Member Gregory H. Bailey to Fund Clinical Milestones
Serina Therapeutics Inc., a Delaware corporation, has entered into a significant financing agreement through an unsecured convertible note with Gregory H. Bailey, M.D., a member of the company's Board of Directors. The agreement, finalized on September 9, 2025, provides Serina Therapeutics access to an aggregate principal amount of up to $20 million. This financial arrangement is structured around the achievement of specific clinical and operational milestones, allowing the company to draw funds in five tranches. The convertible note, which can be converted into Serina common stock at a conversion price of $5.18 per share, aims to support the company's ongoing and future clinical studies, particularly the SER-252-1b registrational clinical study. This development underscores Serina's strategic efforts to bolster its financial resources to advance its research and development initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001708599-25-000110), on September 15, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.